4d Pharma PLC Result of Meeting (8343M)
January 16 2023 - 5:15AM
UK Regulatory
TIDMDDDD
RNS Number : 8343M
4d Pharma PLC
16 January 2023
4D pharma Announces Result of General Meeting
Leeds, UK - January 16, 2023 - 4D pharma plc (AIM: DDDD) (in
administration), a pharmaceutical company leading the development
of Live Biotherapeutic products (LBPs), a novel class of drug
derived from the microbiome, announces that at the General Meeting
held earlier today all resolutions were duly passed.
The full text of each resolution was included in the notice of
the meeting, which was posted to shareholders on 30 December 2022,
and is available on the Company's website www.4dpharmaplc.com .
The results for the resolutions will shortly be available on the
Shareholder Information section of the Company's website,
www.4dpharmaplc.com .
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform, MicroRx
(R) , that rationally identifies Live Biotherapeutics based on a
deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has five clinical programs,
namely a Phase I/II study of MRx0518 in combination with
KEYTRUDA(R) (pembrolizumab) in solid tumors, a Phase I study of
MRx0518 in a neoadjuvant setting for patients with solid tumors, a
Phase I study of MRx0518 in patients with pancreatic cancer, a
Phase I/II study of MRx-4DP0004 in asthma, and Blautix(R) in
Irritable Bowel Syndrome (IBS) which has completed a successful
Phase II trial. Preclinical-stage programs include candidates for
CNS disease such as Parkinson's disease and other neurodegenerative
conditions. The Company has a research collaboration with MSD, a
tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to
discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
Contact Information:
4D pharma
4dpharma@interpathadvisory.com
Singer Capital Markets - Nominated Adviser and Joint Broker
Philip Davies / James Fischer (Corporate Finance) +44 (0)20 7496
3000
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMBFMMTMTMBBMJ
(END) Dow Jones Newswires
January 16, 2023 05:15 ET (10:15 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Nov 2024 to Dec 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Dec 2023 to Dec 2024
